Type IIB DNA topoisomerase is downregulated by trastuzumab and doxorubicin to synergize cardiotoxicity

Despite heightened risk of cardiotoxicity associated with combination therapy of anthracyclines and trastuzumab in HER2-positive breast cancer patients, little research effort has been invested in exploring the molecular mechanisms of cardiotoxicity induced by this combination therapy. In this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Jiangsong, Mohan, Nishant, Endo, Yukinori, Shen, Yi, Wu, Wen Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814198/
https://www.ncbi.nlm.nih.gov/pubmed/29464058
http://dx.doi.org/10.18632/oncotarget.23543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814198/
https://www.ncbi.nlm.nih.gov/pubmed/29464058
http://dx.doi.org/10.18632/oncotarget.23543

Ejemplares similares